Oncology
Oncology is no longer short on platforms. It's short on a way to decide which one survives contact with the biology — and which forward bets are testable, not hopeful.
Engineering the Therapeutic Index
- DOSSIER70–90 pp · 24 figures. ADCs, T-cell engagers, masked constructs, trispecifics and myeloid modulators read as one engineering problem.
- WORKBOOK20 sheets. A 58-trial dated catalyst tracker, five-lever scorecards, 92 audited claims, 167 itemized exclusions.
- AUDIT91.6 / 100, release-ready. 0 fabricated citations across 312 sources.
- HYPOTHESES12 falsifiable, dated — several would refute the conservation law if they fail.
MRD-Guided Neoantigen Vaccines
- DOSSIER60–70 pp · 27 figures. Melanoma, colorectal, lung and pancreatic succeed or fail with the same platform for the same reasons.
- WORKBOOK21 sheets. Dated catalyst tracker, cross-tumor scorecards, 91 audited claims with verbatim excerpts.
- AUDITRelease-ready. Every citation re-checked against primary sources; zero retractions.
- HYPOTHESES13 falsifiable, dated — anchored by BNT122-01, INTerpath-001, AMPLIFY-7P, ctMoniTR.
Exactly what's inside Engineering the Therapeutic Index.
The full research-report table of contents and every one of the 20 tables in the evidence workbook — the real structure of what you license, not a teaser.
- Executive Summary
- Scope and Evidence Integrity
- Decision Snapshot Overview
- Buyer Decision Cheat Sheet
- Source Quality Dashboard
- Therapeutic Index Engineering Model
- Current Signal Update 2025 2026
- Cross Modality Convergence Map
- Evidence Maturity and Platform Matrix
- Competitive and Asset Landscape
- Key Findings
- Quantitative Evidence
- Key Findings Quant Synthesis
- Mechanistic Deep Dive
- Safety Risk and Failure Modes
- Manufacturing Cmc and Feasibility
- Non Obvious Early Opportunities
- Prioritized Hypotheses
- Most Valuable Next Studies
- Validation and Falsification Gates
- Regulatory and Evidence Standards
- Ethical Access and Societal
- Risk Adjusted Market Thesis
- Strategic Recommendations
- Limitations
- Final Judgment
- Expert Review and Validation
- Appendix Methodology and Glossary
- References
Workbook Guide
An orientation to the workbook — its scope, how the claim counts reconcile, and the audit posture.
In this dossier: Tier C evidence workbook for the Next-Generation Immuno-Oncology Platforms dossier. All sources independently re-verified (PubMed/Europe PMC, ClinicalTrials.gov v2, EU…
Claim Ledger
Every factual claim in the report, independently re-verified against its primary source, each carrying a support verdict and a recalibrated evidence grade.
In this dossier: All 90 customer-facing claims, each joined to its independently-verified primary source with a recalibrated grade and support verdict. Evidence layer: Established unless…
Evidence Table
The full registry of cited sources — PMIDs, NCTs and DOIs — with metadata, resolved live against the primary record.
In this dossier: Underlying evidence rows from the source pack (independently re-verified against primary sources in the Claim Ledger).
Source-Support Verdicts
The verbatim source excerpt behind each claim, with an independent verdict on whether the source actually supports it.
In this dossier: Independent per-claim support verdict (SUPPORTS_EXACTLY / SUPPORTS_PARTIALLY / SOURCE_NOT_RETRIEVED) with one-line basis. 0 retractions; 0 contradicts among…
Source Quality Summary
A reconciled view of source quality across the evidence base, with the grading rationale.
In this dossier: Trust section — precise accounting of the evidence base.
Platform Scorecard
Programs or modalities scored on the framework's axes — a structured, side-by-side comparison (expert, ordinal, non-evidentiary).
In this dossier: Comparative platform × five-lever ordinal scores (0–4). EXPERT, FENCED, NON-EVIDENTIARY — a structured comparison of engineering strategy, not efficacy.
Five-Lever Scorecard
Programs or modalities scored on the framework's axes — a structured, side-by-side comparison (expert, ordinal, non-evidentiary).
In this dossier: The model's five levers — what each buys and what it costs (the conservation trade).
Asset Sponsor Tracker
Who is developing what — assets, sponsors and platforms, with the reporting basis made explicit.
In this dossier: Named constructs across modalities — sponsor, target, format/DAR/valency, stage, latest verified readout. Stage/readouts independently verified.
Trial Catalyst Tracker
A dated calendar of trials and readouts — sponsor, phase, indication, and the catalyst that moves the thesis.
In this dossier: All 56 verified trial registry entries (ClinicalTrials.gov v2 + EU CTIS) recovered from kept + excluded claims. Registry listings — no efficacy claim implied.
Safety-Signal Tracker
A structured tracker of the programs, signals and evidence in this dimension of the analysis.
In this dossier: Verified CRS/ICANS (TCEs) and pneumonitis/grade ≥3 (ADCs) by construct — the same Spatial-Activation failure in two payloads.
Resistance Tracker
A structured tracker of the programs, signals and evidence in this dimension of the analysis.
In this dossier: Resistance routes × modality affected × design answer (each answer spends another lever — the conservation trade).
Biomarker-Endpoint Map
How candidate biomarkers map to clinical endpoints — the bridge from a measurement to an outcome.
In this dossier: Biomarker × construct × role — the cheap-currency lever. Predicted biomarkers (protease, myeloid) map to the hypotheses.
Regulatory Tracker
Regulatory designations and pathways relevant to each program — noting that a designation is never an approval.
In this dossier: Approvals, designations, evidentiary basis, and cost-effectiveness — including the surrogate-displacement precedent. Channel named where verified.
Figure Source Map
The provenance of every figure — its underlying data and how it was produced.
In this dossier: Every client-facing figure: family, anchor section, buyer question, data type, source lineage, evidence label, status. No figure is PENDING.
Figure Attempt Ledger
The provenance of every figure — its underlying data and how it was produced.
In this dossier: Figure rendering status — none PENDING. Backend (deterministic/generative) and limitation note per figure.
Hypotheses Ledger
The forward-looking, falsifiable hypotheses — each with a predicted readout and an explicit disconfirming test.
In this dossier: 12 falsifiable, current, cross-lever hypotheses with an explicit disconfirming test and a currency check (none stale).
Most Valuable Next Studies
The highest-leverage experiments to run next, prioritized — a ready-made research agenda.
In this dossier: Nine falsifiable de-risking experiments. Study 1 is the field's pivotal test of the conservation law.
Verification & Search Log
A dated log of the verification searches run — the audit trail behind the evidence.
In this dossier: Every database, query, and date. The source report ran NO external retrieval; this build added a full latest-developments pass.
Excluded Claims
Every claim we considered and removed, with the reason — showing the work, including what didn't make the cut.
In this dossier: All 165 excluded claims re-adjudicated: disposition RECOVER (94) / APPENDIX_TRACKER (63) / EXCLUDE (8). 68/69 beyond-capacity recovered. Counts reconcile 90+165=255.
Salvage Ledger
Claims recovered from the excluded set after deeper verification.
In this dossier: Reuse / improve / replace / re-position decisions versus the source report.
Click any table to see what it is.
Exactly what's inside MRD-Guided Neoantigen Vaccines.
The full research-report table of contents and every one of the 21 tables in the evidence workbook — the real structure of what you license, not a teaser.
- Executive Summary
- Scope and Evidence Integrity
- Decision Snapshot Overview
- Buyer Decision Cheat Sheet
- Source Quality Dashboard
- The Five Axis Translation Model
- Cross Tumor Convergence Map
- Evidence Maturity Matrix and Platform Comparison
- Key Findings
- Quantitative Evidence
- Key Findings Quant Synthesis
- Mechanistic Deep Dive
- Detection and Trigger Design
- Neoantigen Target Quality
- Immune Response and Microenvironment
- Manufacturing and Time to Treat
- Non Obvious Early Opportunities
- Testable Hypotheses
- Most Valuable Next Studies
- Evidence Standards and Regulatory Pathway
- Ethical Access and Societal
- Commercial Market Access and Payer
- Strategic Recommendations
- Limitations
- Final Judgment
- Expert Review and Validation
- Appendix Methodology Glossary
- References
Guide
A structured table within the evidence workbook.
In this dossier: MRD Neoantigen Vaccines — Evidence Workbook · Guide & Reconciliation
Claim Ledger
Every factual claim in the report, independently re-verified against its primary source, each carrying a support verdict and a recalibrated evidence grade.
In this dossier: 90 customer-facing claims (honest tier + role + independent verdict)
Evidence Table
The full registry of cited sources — PMIDs, NCTs and DOIs — with metadata, resolved live against the primary record.
In this dossier: full verified source registry (147 entries)
Source-Support Verdicts
The verbatim source excerpt behind each claim, with an independent verdict on whether the source actually supports it.
In this dossier: Independent Source-Support Verdicts — quantitative anchors (full-text verified)
Source Quality
A reconciled view of source quality across the evidence base, with the grading rationale.
In this dossier: Source Quality Summary — honest re-grade (authoritative PubMed publication type)
Tumor-Type Scorecard
Programs or modalities scored on the framework's axes — a structured, side-by-side comparison (expert, ordinal, non-evidentiary).
In this dossier: Type Scorecard — five axes (ordinal 0–4; expert, non-evidentiary, fenced)
Program-Asset Tracker
A structured tracker of the programs, signals and evidence in this dimension of the analysis.
In this dossier: Program / Asset Tracker — vaccine & ctDNA programs (verified status)
Platform Comparison
A structured table within the evidence workbook.
In this dossier: Platform / Modality Comparison (ordinal 0–4; fenced)
Five-Axis Scorecard
Programs or modalities scored on the framework's axes — a structured, side-by-side comparison (expert, ordinal, non-evidentiary).
In this dossier: Axis Scorecard — programs × Detection×Target×Immune/TME×Manufacturing×Evidentiary (ordinal, fenced)
Trial Tracker
A structured tracker of the programs, signals and evidence in this dimension of the analysis.
In this dossier: Trial / Registry Tracker — every NCT (status, phase, readout timing)
ctDNA Assay Tracker
A structured tracker of the programs, signals and evidence in this dimension of the analysis.
In this dossier: ctDNA / MRD Assay Tracker (verified performance; in-scope)
Surrogate-Validity Map
A structured map across this dimension of the analysis.
In this dossier: Biomarker–Endpoint / Surrogate-Validity Map
Manufacturing Readiness
A structured table within the evidence workbook.
In this dossier: Manufacturing & Logistics Readiness
Regulatory Tracker
Regulatory designations and pathways relevant to each program — noting that a designation is never an approval.
In this dossier: Regulatory & Reimbursement Tracker
Figure Source Map
The provenance of every figure — its underlying data and how it was produced.
In this dossier: every figure, lineage, anchor, sources
Figure Attempt Ledger
The provenance of every figure — its underlying data and how it was produced.
In this dossier: NONE PENDING (was 14 PENDING in source)
Hypotheses Ledger
The forward-looking, falsifiable hypotheses — each with a predicted readout and an explicit disconfirming test.
In this dossier: 13 current, falsifiable (with currency check)
Next Studies
The highest-leverage experiments to run next, prioritized — a ready-made research agenda.
In this dossier: Most Valuable Next Studies / De-risking Experiments
Verification & Search Log
A dated log of the verification searches run — the audit trail behind the evidence.
In this dossier: Verification & Search Log (independent re-assessment + latest-developments search)
Excluded Claims
Every claim we considered and removed, with the reason — showing the work, including what didn't make the cut.
In this dossier: all 64 with dispositions (7 beyond-capacity flagged)
Salvage Ledger
Claims recovered from the excluded set after deeper verification.
In this dossier: recovered excluded + new current additions
Click any table to see what it is.
Different buyers live in different tabs.
Click a buyer to see exactly what they get.
Both dossiers read as one argument about where this field wins.
Buy the pair as the Oncology bundle (vs $8,000 separately). One-time · perpetual · yours to keep.
Every claim resolves to a primary source.
This dossier ships with its independent diligence audit. Evidence is labelled Established / Inferred / Hypothesis. A surrogate is never equated with outcome; a designation is never an approval.
Zemi Research publishes independent, pre-packaged research reports delivered as digital downloads (PDF + spreadsheet). These are information products — not medical, clinical, investment, legal, or professional advice; not a consulting, advisory, or regulated service; and they create no professional-client relationship. Provided for general informational use by industry professionals.